210 related articles for article (PubMed ID: 21817194)
1. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
3. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
4. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
[TBL] [Abstract][Full Text] [Related]
5.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
7. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
[TBL] [Abstract][Full Text] [Related]
10. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
12. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
13. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
[TBL] [Abstract][Full Text] [Related]
14. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
15. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Taylor BS; Hunt G; Abrams EJ; Coovadia A; Meyers T; Sherman G; Strehlau R; Morris L; Kuhn L
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):945-56. PubMed ID: 21345162
[TBL] [Abstract][Full Text] [Related]
16. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
[TBL] [Abstract][Full Text] [Related]
17. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
18. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
20. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
